{"id":379249,"date":"2026-04-10T02:21:39","date_gmt":"2026-04-10T02:21:39","guid":{"rendered":"https:\/\/www.wacoca.com\/life\/379249\/"},"modified":"2026-04-10T02:21:39","modified_gmt":"2026-04-10T02:21:39","slug":"worlds-first-car-t-therapy-for-solid-tumors-available-in-china-soon-jiahui-health%e3%81%ae%e3%83%97%e3%83%ac%e3%82%b9%e3%83%aa%e3%83%aa%e3%83%bc%e3%82%b9","status":"publish","type":"post","link":"https:\/\/www.wacoca.com\/life\/379249\/","title":{"rendered":"World&#8217;s First CAR-T Therapy for Solid Tumors Available in China Soon | Jiahui Health\u306e\u30d7\u30ec\u30b9\u30ea\u30ea\u30fc\u30b9"},"content":{"rendered":"<div>\n<p>A New Hope for Patients with Advanced Gastric and Pancreatic Cancers<\/p>\n<p>\u00a0<\/p>\n<p>SHANGHAI, April 9, 2026 \/PRNewswire\/ &#8212;\u00a0A groundbreaking new CAR-T cell therapy for advanced gastrointestinal cancers is expected to become available in China in the first half of 2026, marking a major step forward in cancer treatment. Jiahui International Cancer Center will be among the leading medical institutions offering access to this innovative therapy for eligible patients.<\/p>\n<p>\u00a0<\/p>\n<p>The therapy, known as satri-cel (CT041), is the world&#8217;s first CAR-T treatment specifically developed for solid tumors targeting Claudin18.2, a biomarker commonly found in gastric (stomach) and pancreatic cancers.<\/p>\n<p>\u00a0<\/p>\n<p>A New Era in Cancer Treatment<\/p>\n<p>\u00a0<\/p>\n<p>CAR-T therapy is a highly personalized treatment that uses a patient&#8217;s own immune cells, reprogrammed to recognize and attack cancer cells with precision. Unlike traditional therapies, CAR-T cells can expand inside the body and continue to fight cancer over time.<\/p>\n<p>\u00a0<\/p>\n<p>While CAR-T has already transformed outcomes in blood cancers, this new therapy represents a major breakthrough in treating solid tumors, where effective options have historically been limited.<\/p>\n<p>\u00a0<\/p>\n<p>Promising Clinical Results<\/p>\n<p>\u00a0<\/p>\n<p>Clinical studies conducted in China have demonstrated encouraging outcomes for patients with advanced gastric and gastroesophageal cancers:<\/p>\n<p>\u00a0<\/p>\n<p>\u30fbObjective response rate (ORR): ~41%, significantly higher than standard treatments<br \/>\u30fbMore than 10x improvement vs. conventional therapies in some comparisons<br \/>\u30fbProgression-free survival extended to ~4.7 months vs. ~1.7 months with standard care<\/p>\n<p>\u00a0<\/p>\n<p>These results have been presented at leading international conferences and published in top-tier medical journals, highlighting the global significance of this therapy.<\/p>\n<p>\u00a0<\/p>\n<p>Addressing a Major Unmet Need<\/p>\n<p>\u00a0<\/p>\n<p>Advanced gastric and pancreatic cancers remain among the most difficult cancers to treat, with limited effective options in later lines of therapy and poor survival outcomes.<\/p>\n<p>\u00a0<\/p>\n<p>This CAR-T therapy offers a new treatment pathway for patients who have exhausted conventional options.<\/p>\n<p>\u00a0<\/p>\n<p>Who May Benefit<\/p>\n<p>\u00a0<\/p>\n<p>This therapy may be suitable for patients who:<\/p>\n<p>\u00a0<\/p>\n<p>\u30fbHave advanced or metastatic gastric or gastroesophageal cancer<br \/>\u30fbHave received at least two prior lines of treatment<br \/>\u30fbShow Claudin18.2-positive tumors<br \/>\u30fbMeet clinical eligibility criteria<\/p>\n<p>\u00a0<\/p>\n<p>Each patient will undergo a detailed medical evaluation to determine suitability.<\/p>\n<p>\u00a0<\/p>\n<p>Looking Ahead<\/p>\n<p>\u00a0<\/p>\n<p>This therapy represents a milestone in oncology, opening the door for CAR-T treatments beyond blood cancers and into solid tumors.<\/p>\n<p>\u00a0<\/p>\n<p>Ongoing research is exploring broader applications, including earlier-stage treatment and additional tumor types.<\/p>\n<p>\u00a0<\/p>\n<p>Contact Information<\/p>\n<p>\u00a0<\/p>\n<p>For more information, teleconsultation appointments and eligibility assessments please contact:<\/p>\n<p>\u00a0<\/p>\n<p>Jiahui Japanese Service Email: <a href=\"https:\/\/kyodonewsprwire.jp\/release\/mailto:jih.jpcrm@jiahui.com\" target=\"_blank\" rel=\"noopener nofollow\">jih.jpcrm@jiahui.com<\/a>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>Full article: <a href=\"https:\/\/jiahui.com\/en\/news\/200\" target=\"_blank\" rel=\"noopener nofollow\">https:\/\/jiahui.com\/en\/news\/200<\/a>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>PR Newswire Asia Ltd.<\/p>\n<p>\u00a0<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.wacoca.com\/life\/wp-content\/uploads\/2026\/04\/_prw_OI1ic_4W4O10Dc.jpg\" width=\"160\" height=\"80\" data-shiryoid=\"1\"\/><\/p>\n<p>\u00a0<\/p>\n<p>PR Newswire<br \/>1954\u5e74\u306b\u8a2d\u7acb\u3055\u308c\u305f\u4e16\u754c\u521d\u306e\u7c73\u56fd\u5e83\u5831\u901a\u4fe1\u793e\u3067\u3059\u3002\u914d\u4fe1\u30cd\u30c3\u30c8\u30ef\u30fc\u30af\u3067\u5168\u4e16\u754c\u3092\u30ab\u30d0\u30fc\u3057\u3066\u3044\u307e\u3059\u3002Cision Ltd.\u306e\u5b50\u4f1a\u793e\u3068\u3057\u3066\u3001Cision\u30af\u30e9\u30a6\u30c9\u30d9\u30fc\u30b9\u30b3\u30df\u30e5\u30cb\u30b1\u30fc\u30b7\u30e7\u30f3\u88fd\u54c1\u3001\u4e16\u754c\u6700\u5927\u306e\u30de\u30eb\u30c1\u30c1\u30e3\u30cd\u30eb\u3001\u591a\u6587\u5316\u30b3\u30f3\u30c6\u30f3\u30c4\u666e\u53ca\u30cd\u30c3\u30c8\u30ef\u30fc\u30af\u3068\u5305\u62ec\u7684\u306a\u30ef\u30fc\u30af\u30d5\u30ed\u30fc\u30c4\u30fc\u30eb\u304a\u3088\u3073\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3092\u7d44\u307f\u5408\u308f\u305b\u308b\u3053\u3068\u3067\u3001\u69d8\u3005\u306a\u7d44\u7e54\u306e\u30b9\u30c8\u30fc\u30ea\u30fc\u3092\u652f\u3048\u3066\u3044\u307e\u3059\u3002<a href=\"http:\/\/www.prnasia.com\/\" target=\"_blank\" rel=\"noopener nofollow\">www.prnasia.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>A New Hope for Patients with Advanced Gastric and Pancreatic Cancers \u00a0 SHANGHAI, April 9, 2026 \/PRNewswire\/ &#038;#<\/p>\n","protected":false},"author":2,"featured_media":379250,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[3],"tags":[6004,156877,2700],"class_list":{"0":"post-379249","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-health","9":"tag-kenko","10":"tag-2700"},"share_on_mastodon":{"url":"https:\/\/wakoka.com\/@life\/116378032278595188","error":""},"_links":{"self":[{"href":"https:\/\/www.wacoca.com\/life\/wp-json\/wp\/v2\/posts\/379249","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wacoca.com\/life\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wacoca.com\/life\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wacoca.com\/life\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wacoca.com\/life\/wp-json\/wp\/v2\/comments?post=379249"}],"version-history":[{"count":0,"href":"https:\/\/www.wacoca.com\/life\/wp-json\/wp\/v2\/posts\/379249\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wacoca.com\/life\/wp-json\/wp\/v2\/media\/379250"}],"wp:attachment":[{"href":"https:\/\/www.wacoca.com\/life\/wp-json\/wp\/v2\/media?parent=379249"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wacoca.com\/life\/wp-json\/wp\/v2\/categories?post=379249"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wacoca.com\/life\/wp-json\/wp\/v2\/tags?post=379249"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}